Her2/neu Vaccine Protects Against Tumor Growth
- Detailed Technology Description
- University of California, Irvine researchers have developed a recombinant polynucleotide encoding Her2/neu target antigen. This recombinant polynucleotide contains two regions of the human Her2/neu molecule which demonstrated the lowest degree of homology with other known normal human proteins as the putative target antigen sequence for a genetic vaccination strategy. This target sequence was chosen to minimize any potential cross reactive auto-immune response and to maximize specificity of the elicited immune response. These portions of human Her2/neu contain some of the previously identified T cell epitopes. Because this sequence is predominantly intracellular and represents a truncated or partial protein sequence, the protein is anticipated to be rapidly degraded and presented in the context of MHC class I and thus be available for CTL recognition.
- Supplementary Information
- Patent Number: US7446185B2
Application Number: US2003484067A
Inventor: Nelson, Edward L.
Priority Date: 18 Jul 2001
Priority Number: US7446185B2
Application Date: 19 May 2004
Publication Date: 4 Nov 2008
IPC Current: C07H002104 | C07K001400 | C07K001447 | C12N000510 | C12N001511 | C12N001563 | A61K003800 | A61K003900
US Class: 5360231 | 4353201 | 435325 | 530350
Assignee Applicant: The Regents of the University of California
Title: Her2/neu target antigen and use of same to stimulate an immune response
Usefulness: Her2/neu target antigen and use of same to stimulate an immune response
Summary: The polynucleotide encoding a Her2/neu target antigen is useful for stimulating immunoeffector cells or an immune response in a subject against cancer cells expressing Her2/neu. The encoded Her2/neu target antigen polypeptide is useful as a tag to detect or isolate the fusion protein containing the Her2/neu target an immune response stimulated by the Her2/neu target antigen. The Her2/neu target antigen polynucleotides and polypeptides are useful in genetic or polypeptide vaccination strategies.
Novelty: New Her2/neu target antigens and polynucleotides encoding them, useful for stimulating immunoeffector cells or an immune response in a subject against cancer cells expressing Her2/neu, and for vaccination strategies
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- Application No.
- 7446185
- Others
-
Tech ID/UC Case
18903/2001-288-0
Related Cases
2001-288-0
- *Abstract
-
Her2/neu is over-expressed in various types of tumor cells, including 20-30% of breast cancers, adenocarcinomas of the ovary, salivary gland, stomach and kidney, colon cancer, and non-small cell lung cancer. Passive immunotherapeutics like Herceptin control and prevent further tumor cell growth. Unlike active immunotherapeutics, Herceptin does not mediate the immunological cellular destruction.
Active immunotherapeutics such as vaccines elicit T helper-1 (Th1) and Cytotoxic T lymphocytes (CTL) biased immune responses and are generally observed for proteins expressed in the intracellular compartment, and less prominently with extracellular or secreted proteins. Rapid degradation of a protein containing polyepitopes can contribute to establishing a bias in the immune response, facilitate antigen presentation and, perhaps assist in establishing specificity of the immune response. This type of immunological response should result in immunological cellular destruction.
- *IP Issue Date
- Nov 4, 2008
- *Principal Investigator
-
Name: Edward Nelson
Department:
- Country/Region
- USA
